Insights

Medicines Access

The 21st Century Cures Act: Turn your obligations into an advantage

The 21st Century Cures Act (21CCA), which came into effect in February 2017, is intended to help accelerate the development of medicines and bring those medicines to patients more quickly.…
Update

Pre-Approval Access Policy

Policies on pre-approval access (‘early access’, ‘expanded access’ etc.) have come into focus since the enactment of the US 21st Century Cures Act. Driven by the requirements of the Act,…
Clinical Trial Services

Navigating the Clinical Trial Supply Route in China

Inceptua has been actively operating in China for almost 20 years and is continuing to expand capabilities throughout the APAC region. Our office in Shanghai is where our specialist China…
Update
Small Data for a Big Benefit
Clinical Trial Services
Inceptua Q&A: Comparator Sourcing for Clinical Trials
Medicines Access
Expediting Access to Rare Disease Therapies in Europe
Medicines Access
Providing Access to Unlicensed Medicines
Clinical Trial Services
How to navigate the challenges of a changing Chinese market
Featured
Commercialize and partner successfully in Europe and the Middle East
Clinical Trial Services
Race the hurdles of global clinical trials
Medicines Access
What life science companies need to know about pre-approval access
Update
Pre-Approval Access – the Theory and the Practicality
Update
Time for clarity on RWD in Early Access Programs
Update
Pre-approval access in Europe for US biotechs – the secret to success?

News and Press Releases

Featured

Inceptua and Portola enter exclusive distribution agreement for Ondexxya®

LUXEMBOURG / SAN FRANCISCO – LUXEMBOURG / SAN FRANCISCO – 7th February  2020 –  – Inceptua, a global pharmaceutical company and service partner and Portola - US developer and manufacturer…
Featured

Inceptua appoints new Head of Asia-Pacific, Clinical Trial Services

Inceptua has offices in both Japan and China where the regional Clinical Trial Services Team provides strategic sourcing and supply of clinical trial materials with associated clinical packaging and labelling…
Press release

Inceptua and Onconova Therapeutics Announce Pre-approval Access Collaboration for Rigosertib in Selected Countries Outside the US

NEWTOWN, PA., and LUXEMBOURG, Dec 6, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with…
Press release
Inceptua appoints new President North America
Press release
Inceptua and Bendalis enter into an exclusive oncology medicine supply agreement for clinical trials
Press release
Inceptua appoints new CEO
News
HAEi Global Access Program Provides Life-saving Medication
Press release
Head of Global Patient Access joins Inceptua
Press release
New Chief Medical Officer joins Inceptua
Press release
Strong industry profiles join Inceptua
Press release
Creation of Inceptua Clinical Trial Services marks new era for the company
News
Pharming Group and HAEi International announce partnership with Inceptua for HAEi Global Access Program
Press release
Industry experts set to transform evolving pre-approval & unlicensed medicines sector with launch of Inceptua Medicines Access